|
Particular treatments effective for alcohol dependence
May 03, 2006Medical management combined with the drug naltrexone or with a specialized behavioral therapy can be effective treatments for alcohol dependence, according to a study in the May 3 issue of JAMA.
About 8 million individuals in the U.S. currently meet diagnostic criteria for alcohol dependence (also called alcoholism), a leading preventable cause of illness and death and a major contributor to health care costs, according to background information in the article. In primary care settings, the prevalence of alcohol use disorders ranges from 20 percent to 36 percent; most of those patients are never treated and, if they are, do not receive specialty care. Several behavioral treatments and at least two medications approved by the U.S. FDA, naltrexone and acamprosate, have shown efficacy in the treatment of alcohol dependence. However, no large-scale randomized controlled study has evaluated whether combined drug treatment with or without behavioral therapy could improve outcome.
Raymond F. Anton, M.D., of the Medical University of South Carolina, Charleston, and colleagues evaluated the effectiveness in treating alcohol dependence with medical management and naltrexone, acamprosate, or both, with or without combined behavioral intervention (CBI) provided by behavioral health specialists. The trial (the COMBINE Study), conducted from January 2001 - January 2004, included 1,383 recently alcohol-abstinent volunteers with a diagnosis of primary alcohol dependence. The participants were divided into 9 groups. Eight groups of patients received medical management with 16 weeks of naltrexone or acamprosate, both, and/or both placebos, with or without CBI. Medical management included sessions with a medical professional focused on enhancing medication adherence and alcohol abstinence. A ninth group received CBI only (no pills). Patients were evaluated for up to one year after treatment.
The researchers found that all groups showed substantial reduction in drinking. During treatment, patients receiving naltrexone plus medical management, CBI plus medical management and placebos, or both naltrexone and CBI plus medical management had higher percentages of days abstinent (80.6, 79.2, and 77.1, respectively) than the 75.1 in those receiving placebos and medical management only. Naltrexone also reduced the risk of a heavy drinking day over time, most evident in those receiving medical management but not CBI.
Acamprosate showed no significant effect on drinking compared with placebo, either by itself or with any combination of naltrexone, CBI, or both. During the 16 weeks of treatment, there was an overall difference in percent days abstinent between those receiving placebo pills and medical management alone (73.8), placebo pills and medical management plus CBI (79.8), and CBI alone (no pills or medical management) (66.6). One year after treatment, these between-group effects were similar but no longer significant.
"In conclusion, within the context of medical management, naltrexone yielded outcomes similar to those obtained from specialist behavioral treatment (i.e., CBI). We found no evidence of efficacy for acamprosate and also no evidence of incremental efficacy for combinations of naltrexone, acamprosate, and CBI. Somewhat unexpectedly, we observed a positive effect of receiving placebo medication and medical management over and above that seen with specialist-delivered behavioral therapy alone. Medical management of alcohol dependence with naltrexone appears to be feasible and, if implemented in primary, and other, health care settings, could greatly extend patient access to effective treatment. Future studies that evaluate the usefulness of continued or intermittent care of alcohol-dependent individuals over the longer term should be considered," the authors write.
JAMA and Archives Journals
The researchers found that all groups showed substantial reduction in drinking. During treatment, patients receiving naltrexone plus medical management, CBI plus medical management and placebos, or both naltrexone and CBI plus medical management had higher percentages of days abstinent (80.6, 79.2, and 77.1, respectively) than the 75.1 in those receiving placebos and medical management only. Naltrexone also reduced the risk of a heavy drinking day over time, most evident in those receiving medical management but not CBI.
Acamprosate showed no significant effect on drinking compared with placebo, either by itself or with any combination of naltrexone, CBI, or both. During the 16 weeks of treatment, there was an overall difference in percent days abstinent between those receiving placebo pills and medical management alone (73.8), placebo pills and medical management plus CBI (79.8), and CBI alone (no pills or medical management) (66.6). One year after treatment, these between-group effects were similar but no longer significant.
"In conclusion, within the context of medical management, naltrexone yielded outcomes similar to those obtained from specialist behavioral treatment (i.e., CBI). We found no evidence of efficacy for acamprosate and also no evidence of incremental efficacy for combinations of naltrexone, acamprosate, and CBI. Somewhat unexpectedly, we observed a positive effect of receiving placebo medication and medical management over and above that seen with specialist-delivered behavioral therapy alone. Medical management of alcohol dependence with naltrexone appears to be feasible and, if implemented in primary, and other, health care settings, could greatly extend patient access to effective treatment. Future studies that evaluate the usefulness of continued or intermittent care of alcohol-dependent individuals over the longer term should be considered," the authors write.
JAMA and Archives Journals
Alcohol Dependence News and Current Alcohol Dependence Events RSSInitiating drinking at younger age heightens women's risk for alcohol dependence
Women born after 1944 began drinking alcohol at younger ages than their elders, and that appears to have put them at greater risk for alcoholism, according to researchers at Washington University School of Medicine in St. Louis.
Study finds link between amphetamine abuse and heart attacks in young adults
Young adults who abuse amphetamines may be at greater risk of suffering a heart attack, UT Southwestern Medical Center researchers have found.
Report confirms increased risk of smoking, substance abuse in bipolar adolescents
A study from the Massachusetts General Hospital (MGH) supports previous reports that adolescents with bipolar disorder are at increased risk for smoking and substance abuse.
Drinking at an early age can lead to later alcohol dependence
An early age at onset of drinking (AOD) is a strong predictor of subsequent alcohol dependence (AD). Following through on previous research that found substantial increases in drinking and AD among women born between 1944 - 1983, compared to women born between 1934 - 1943, this study examined the influence of AOD.
Students with a dense family history of alcoholism are most at risk of alcohol-use disorders
While many university students tend to "mature out" of heavy-drinking behavior by the time they become young adults, some go on to develop alcohol-use disorders (AUDs).
New study reveals brain cell mechanism of alcohol dependence
A study released today reveals a cellular mechanism involved in alcohol dependence. The study, in the May 28 issue of The Journal of Neuroscience, shows that gabapentin, a drug used to treat chronic pain and epilepsy, reduces alcohol intake in alcohol-dependent rats by normalizing chemical communication between neurons, which is altered by chronic alcohol abuse.
Scripps Research scientists find seizure drug reverses cellular effects
In the new research, published in the May 28, 2008 edition of The Journal of Neuroscience, the scientists found that gabapentin normalizes the action of certain brain cells altered by chronic alcohol abuse in an area of the brain known as the central amygdala, which plays an important role in fear- and stress-related behaviors, as well as in regulating alcohol drinking. In the study, alcohol-dependent rodents receiving gabapentin drank less alcohol.
Are Anxiety Disorders All in the Mind?
Using single-photon emission computed tomography (SPECT), researchers in The Netherlands were able to detect biochemical differences in the brains of individuals with generalized social anxiety disorder (also known as social phobia), providing evidence of a long-suspected biological cause for the dysfunction.
Naltrexone is effective for Alaska Natives and other Alaskans living in rural areas
Access to treatment for alcohol dependence (AD) in rural and remote areas is limited.
The tachykinin receptor 3 gene has been linked to alcohol and cocaine dependence
The search for genes associated with alcohol dependence has recently been extended to the tachykinin receptor 3 gene, located within a broad region on chromosome 4q. Researchers have found that seven of the nine single nucleotide polymorphisms -- DNA sequence variations -- in the 3' region of TACR3 have a significant association with AD as well as cocaine dependence.
More Alcohol Dependence News Articles
 | Living Sober by AA Services |
 | 7 Weeks to Safe Social Drinking: How to Effectively Moderate Your Alcohol Intake by Donna J. Cornett |
 | Freedom from Addiction: The Chopra Center Method for Overcoming Destructive Habits by Deepak Chopra, M.D., David Simon |
 | Leaving Dirty Jersey: A Crystal Meth Memoir by James Salant |
 | Pihkal: A Chemical Love Story by Alexander Shulgin, Ann Shulgin |
 | The Tao of Sobriety: Helping You to Recover from Alcohol and Drug Addiction by David Gregson, Jay S. Efran, G. Alan Marlatt |
 | No More Letting Go: The Spirituality of Taking Action Against Alcoholism and Drug Addiction by Debra Jay |
 | Tihkal: The Continuation by Alexander Shulgin |
 | The Alcoholism and Addiction Cure: A Holistic Approach to Total Recovery by Chris Prentiss |
 | Staying Clean: Living Without Drugs by Anonymous |
| © 2008 BrightSurf.com |